PE20070717A1 - Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida - Google Patents

Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida

Info

Publication number
PE20070717A1
PE20070717A1 PE2006001368A PE2006001368A PE20070717A1 PE 20070717 A1 PE20070717 A1 PE 20070717A1 PE 2006001368 A PE2006001368 A PE 2006001368A PE 2006001368 A PE2006001368 A PE 2006001368A PE 20070717 A1 PE20070717 A1 PE 20070717A1
Authority
PE
Peru
Prior art keywords
iminometil
carbonylamine
polymorph
dimethylamine
carboxamide
Prior art date
Application number
PE2006001368A
Other languages
English (en)
Inventor
Craig Grant
James P Kanter
Graeme Langlands
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20070717A1 publication Critical patent/PE20070717A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE [2-({4-[(DIMETILAMINO)IMINOMETIL]FENIL}CARBONILAMINO)-5-METOXIFENIL]-N-(5-CLORO-(2-PIRIDIL))CARBOXAMIDA Y UN ACIDO DE PREFERENCIA ACIDO MALEICO, ACIDO PROPIONICO, CARACTERIZADO PORQUE CONTIENE UN PATRON DE DIFRACCION DE RAYOS X EN POLVO DE 4,9; 9,7; 13,8; 14,1; 15,2; 20,8; ENTRE OTROS (GRADO 2 THETA). REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO POLIMORFO ES INHIBIDOR DEL FACTOR Xa, UTIL EN EL TRATAMIENTO DE SINDROME CORONARIO AGUDO, INFARTO DE MIOCARDIO, ANGINA INESTABLE, EMBOLIA PULMONAR, ENTRE OTROS
PE2006001368A 2005-11-08 2006-11-07 Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida PE20070717A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73522405P 2005-11-08 2005-11-08

Publications (1)

Publication Number Publication Date
PE20070717A1 true PE20070717A1 (es) 2007-08-17

Family

ID=38023988

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006001368A PE20070717A1 (es) 2005-11-08 2006-11-07 Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
PE2010000471A PE20110070A1 (es) 2005-11-08 2006-11-07 Procedimiento de preparacion del compuesto [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro(2-piridil))carboxamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2010000471A PE20110070A1 (es) 2005-11-08 2006-11-07 Procedimiento de preparacion del compuesto [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro(2-piridil))carboxamida

Country Status (21)

Country Link
US (7) US7598276B2 (es)
EP (2) EP2431358A1 (es)
JP (2) JP5227178B2 (es)
KR (1) KR101358574B1 (es)
CN (2) CN101304971B (es)
AR (2) AR056787A1 (es)
AT (1) ATE549317T1 (es)
AU (1) AU2006311544B2 (es)
BR (1) BRPI0618362A2 (es)
CA (1) CA2627086C (es)
DK (1) DK1948608T3 (es)
ES (1) ES2384116T3 (es)
HK (1) HK1115131A1 (es)
IL (2) IL190524A (es)
NZ (2) NZ567992A (es)
PE (2) PE20070717A1 (es)
PT (1) PT1948608E (es)
RU (1) RU2440986C2 (es)
TW (1) TWI443088B (es)
WO (1) WO2007056517A2 (es)
ZA (1) ZA200803820B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
CA2627086C (en) * 2005-11-08 2016-04-05 Millennium Pharmaceuticals, Inc. Novel pharmaceutical salts and polymorphs of a factor xa inhibitor
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
TW200813017A (en) * 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
CA2913963A1 (en) * 2006-12-08 2008-06-19 Millenium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
AU2008205093A1 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
CN103071154A (zh) 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
EP2146705B1 (en) * 2007-05-02 2014-03-05 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
BR122022001846B1 (pt) 2007-09-28 2022-12-27 Portola Pharmaceuticals, Inc. Uso de polipeptídeo de duas cadeias para preparo de medicamento para reduzir sangramento
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010117729A1 (en) 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
WO2011084519A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor xa inhibitors
EP2513094B1 (en) * 2009-12-17 2015-12-16 Millennium Pharmaceuticals, Inc. Crystalline salts of a factor xa inhibitor
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
AR082803A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
WO2013033370A1 (en) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) * 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
CN113171447B (zh) 2014-08-20 2024-05-17 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
WO2017091757A1 (en) * 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
US20190046450A1 (en) 2016-02-24 2019-02-14 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
CA3027457A1 (en) 2016-06-17 2017-12-21 Portola Pharmaceuticals, Inc. Preparation of factor xa derivatives
WO2018042320A1 (en) * 2016-08-30 2018-03-08 Dr. Reddy’S Laboratories Limited Salts of betrixaban and processes for preparation thereof
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN108017576B (zh) * 2016-11-01 2022-06-21 石药集团中奇制药技术（石家庄）有限公司 一种贝曲西班及其盐酸盐的制备方法，以及它们的晶型
CN108586325A (zh) * 2017-03-16 2018-09-28 上海度德医药科技有限公司 一种Betrixaban中间体的制备方法
WO2018229796A2 (en) * 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
WO2022211680A1 (ru) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Способ получения антикоагулянта n-(5-хлорпиридин-2-ил)-2-({4-[этан-имидоил(метил)амино]бензоил}амино)-5-метилбензамид гидрохлорида
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013693A1 (en) 1992-12-15 1994-06-23 Corvas International, Inc. NOVEL INHIBITORS OF FACTOR Xa
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
PT798295E (pt) 1994-12-02 2003-07-31 Yamanouchi Pharma Co Ltd Novo derivado de amidinonaftilo ou sal deste
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
EA003056B1 (ru) 1996-12-23 2002-12-26 Дюпон Фармасьютикалз Компани АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
AU8747598A (en) 1997-08-27 1999-03-16 Kissei Pharmaceutical Co. Ltd. 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
CA2385592C (en) 1999-09-17 2011-01-11 Bing-Yan Zhu Benzamides and related inhibitors of factor xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2627086C (en) 2005-11-08 2016-04-05 Millennium Pharmaceuticals, Inc. Novel pharmaceutical salts and polymorphs of a factor xa inhibitor
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor

Also Published As

Publication number Publication date
BRPI0618362A2 (pt) 2011-08-30
DK1948608T3 (da) 2012-07-02
TWI443088B (zh) 2014-07-01
PE20110070A1 (es) 2011-03-04
EP1948608A2 (en) 2008-07-30
ZA200803820B (en) 2009-03-25
CN102336702A (zh) 2012-02-01
US20170326119A1 (en) 2017-11-16
JP2012246323A (ja) 2012-12-13
US20100063113A1 (en) 2010-03-11
CN101304971A (zh) 2008-11-12
JP5662980B2 (ja) 2015-02-04
ES2384116T3 (es) 2012-06-29
HK1115131A1 (en) 2008-11-21
ATE549317T1 (de) 2012-03-15
KR101358574B1 (ko) 2014-02-04
IL190524A0 (en) 2008-12-29
TW200736221A (en) 2007-10-01
CN102336702B (zh) 2015-02-11
US20140288028A1 (en) 2014-09-25
US7598276B2 (en) 2009-10-06
EP1948608B1 (en) 2012-03-14
AU2006311544B2 (en) 2012-03-08
US9061019B2 (en) 2015-06-23
US20160101089A1 (en) 2016-04-14
KR20080065662A (ko) 2008-07-14
US9555023B2 (en) 2017-01-31
IL213487A0 (en) 2011-07-31
RU2008123055A (ru) 2009-12-20
WO2007056517A3 (en) 2008-04-17
AR106960A2 (es) 2018-03-07
NZ567992A (en) 2011-05-27
US8557852B2 (en) 2013-10-15
PT1948608E (pt) 2012-05-24
JP5227178B2 (ja) 2013-07-03
AR056787A1 (es) 2007-10-24
NZ592533A (en) 2012-08-31
JP2009514976A (ja) 2009-04-09
US20130064806A1 (en) 2013-03-14
US20190046510A1 (en) 2019-02-14
CN101304971B (zh) 2011-09-07
AU2006311544A1 (en) 2007-05-18
CA2627086C (en) 2016-04-05
IL190524A (en) 2013-02-28
WO2007056517A2 (en) 2007-05-18
RU2440986C2 (ru) 2012-01-27
US20070112039A1 (en) 2007-05-17
CA2627086A1 (en) 2007-05-18
EP2431358A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
PE20070717A1 (es) Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
NO2016009I2 (no) Sakubitril/valsartan, inkludert farmasøytisk akseptable salter derav
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
JP2007507551A5 (es)
JP2010505906A5 (es)
PE20120812A1 (es) Compuestos vinil indazolilo
PE20110136A1 (es) Compuestos organicos
PE20100731A1 (es) Inhibidores heterociclicos de la aspartil proteasa
PE20060877A1 (es) Compuestos y composiciones como inhibidores de la kinasa proteica
PE20141318A1 (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando acidos organicos
RU2011138970A (ru) Активаторы растворимой гуанилатциклазы
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
TW200626142A (en) Chemical compounds
PE20070806A1 (es) Composicion farmaceutica que comprende un derivado de diarilurea
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
JP2007505901A5 (es)
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PE20091565A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
PE20070640A1 (es) Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
TW200738588A (en) Chemical compounds
PE20071225A1 (es) Compuestos derivados de piperidina como inhibidores de neurocinina-1 (nk-1) y del transportador de serotonina
JP2005527523A5 (es)
JP2004520438A5 (es)
JP2005506970A5 (es)

Legal Events

Date Code Title Description
FG Grant, registration